(Total Views: 990)
Posted On: 12/21/2020 1:20:49 AM
Post# of 153939
Cost & Inventory Accounting Manager.
CytoDyn is a publicly traded late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. It has filed a BLA with the FDA and, if approved, commercial sales could commence in early 2021. The Company is also rapidly exploring COVID-19 and various cancer indications. The Company recently filed a BLA for HIV with the FDA and, if approved, commercial sales could commence in early 2021, or sooner. The Company is also rapidly evaluating its drug, leronlimab, to treat COVID-19 and various forms of cancer.
CytoDyn is a publicly traded late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. It has filed a BLA with the FDA and, if approved, commercial sales could commence in early 2021. The Company is also rapidly exploring COVID-19 and various cancer indications. The Company recently filed a BLA for HIV with the FDA and, if approved, commercial sales could commence in early 2021, or sooner. The Company is also rapidly evaluating its drug, leronlimab, to treat COVID-19 and various forms of cancer.
(2)
(0)
